Professor Raghib Ali OBE is the Chief Investigator, Interim CEO, and Chief Medical Officer of Our Future Health; a Clinical Epidemiologist at the University of Cambridge; a Consultant in Acute Medicine at the Oxford University Hospitals NHS Trust; and an Honorary Consultant with the Office for Health Disparities and Improvement. He graduated from Cambridge University and has been awarded postgraduate degrees in Epidemiology and Public Health from the Universities of London, Cambridge, and Oxford and is a Fellow of the Royal College of Physicians. He has been involved in population health research since 2004 nationally and globally, working firstly on the UK Biobank, then leading studies of cancer incidence by ethnic group in England and India from 2005 to 2013, and established the UAE Healthy Future Study, in 2014, for which he is the principal investigator.

Dr. Al-Yamany is the Sector Head for Health, Wellbeing & Biotech at NEOM. Leading the advancement of innovative and technological healthcare and wellbeing, he has extensive experience in neurosurgery & healthcare administration in multiple organizations. Additionally, he is an Assistant Professor of Neurosurgery at KSAHU & an Adjunct Professor of Health Management at Desautels College of McGill University. With a Masters in Executive Health Administration from the United States and a Medical Degree from King Saud’s University, Al-Yamany has served across a variety of roles, including Executive Medical Director, CEO & Board Chairman. He is also a notable member of professional associations such as the American Board and the Canadian Board of Neurosurgery.

Dr.Steven Austad is the Senior Scientific Director and Interim Board of Directors’ Chair of the American Federation for Aging Research. He is also a Distinguished Professor and the Protective Life Endowed Chair in Healthy Aging Research in the Department of Biology at the University of Alabama at Birmingham (UAB). In addition, he is the Founding Director and current Co-director of UAB’s Nathan Shock Center of Excellence in the Basic Biology of Aging. He has published more than 200 scientific papers and 7 books and has authored more than 150 essays and op-eds in print and electronic media.

Dr. Salvador Aznar Benitah obtained his Honours degree in Biochemistry and Molecular Biology at McGill University in 1998. In 2007, after postdoctoral work at the London Research Institute (CRUK), he established his lab at the Center for Genomic Regulation. In 2014 Salvador was promoted to ICREA Professor and moved to the IRB Barcelona as a senior researcher where he became the coordinator of the Aging and Metabolism Program in 2023. Salvador is the recipient of several awards including the Banc Sabadell, Doctor Diz Pintado, Beug Foundation Metastasis, City of Barcelona, National Award, the Foundation Serra, the Severo Ochoa, and the Lilliane Bettencourt. He is an EMBO member and has received an Advanced ERC grant.

Following an academic background at Harvard, MIT, and Caltech, inventing over 100 patents and applications, founding two prior companies with a combined 185 employees, spending 2 years as a part-time partner at Y Combinator, investing in and advising numerous biotechs, and publishing a Science paper in biophysics, Joe is now the CEO of Retro Biosciences, which uses high-throughput, high-dimensional approaches to develop therapies for diseases driven by the biology of aging.

Dr. Arthur Caplan is the Drs. William F. and Virginia Connolly Mitty Professor and founding head of the Division of Medical Ethics at the NYU Grossman School of Medicine in New York City. Dr. Caplan is the author or editor of thirty-five books and over 865 papers in peer-reviewed journals.  Dr. Caplan is the recipient of many awards and honors, including the McGovern Medal of the American Medical Writers Association, a USA Today 2001 “Person of the Year” and was described as one of the ten most influential people in science by Discover magazine in 2008.

Named by Fortune as one of the “World’s 50 Greatest Leaders,” Dr.Peter Diamandis is the Founder and Executive Chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. Peter is Co-founder and Vice-Chairman of two public companies, Celularity and Vaxxinity. Diamandis is Co-founder & Chairman of Fountain Life, a platform delivering preventative, personalized and data-driven health. Peter is Co-founder of BOLD Capital Partners, a venture fund with $500B under management investing in exponential technologies and longevity companies. He earned degrees in molecular genetics and aerospace engineering from MIT and holds an M.D. from Harvard Medical School.

Dr. Peter Fedichev is the Co-founder of Gero, a data-driven longevity biotech company, that develops new drugs against aging and other complex diseases using an AI-platform. He is an author of 75+ published papers in multiple domain areas, including publications in Science and Nature Communications. He earned his Ph.D. from the University of Amsterdam.

David Gems is Professor of Biogerontology at the UCL Institute of Healthy Ageing, of which he is a founder member and Research Director. He has a B.Sc. in Biochemistry and a Ph.D. in Genetics. He was a postdoc at the University of Missouri before starting his own research group at UCL in 1997. The aims of his research are to understand the causes of aging and to identify general principles of pathophysiology for late-life diseases. Much of his work uses the nematode worm C. elegans, but he has also contributed to studies of aging in Drosophila and the mouse.

Simone Gibertoni is the CEO of Clinique La Prairie, and co-founder of Holistic Health by Clinique La Prairie (longevity supplements). Clinique La Prairie is the world's most exclusive clinic and one of the most iconic Swiss brands. Simone is driving the international development of Clinique La Prairie and its diversification strategy, with the mission of creating a global player able to help people live a longer, healthier and better life. Simone is a renowned keynote speaker, presenting at leading conferences, and universities. He frequently shares insights on wellness, longevity, business, and luxury strategies, with his thoughts on business and longevity featured in top international journals.

Vadim Gladyshev is a Professor of Medicine at Harvard Medical School, Director of the Center for Redox Medicine at Brigham and Women's Hospital, and faculty member of the Broad Institute. Dr. Gladyshev’s lab focuses on studying aging, rejuvenation, and lifespan control using a combination of experimental and computational approaches. He has published more than 400 articles. Dr. Gladyshev is the recipient of NIH Pioneer, Transformative and Eureka awards and is an elected member of the National Academy of Sciences, USA.

David Gobel heads the Methuselah Foundation, a medical charity that was organized in 2000 and is based in Springfield, Virginia. Under Gobel's leadership, Methuselah has invested millions of dollars to support research and development in regenerative medicine and is actively involved in efforts to change how the public thinks about extending the healthy human lifespan. Gobel established Methuselah in order to, as stated on its original website, "shed light on the processes of aging and find ways to extend healthy life." The organization works in a variety of ways: Incubating companies that are developing breakthrough technologies, supporting mission-relevant ventures that promote longevity research, funding such research directly, and supporting projects and prizes to accelerate breakthroughs in longevity.

James L. Kirkland, M.D., Ph.D., a specialist in internal medicine, geriatrics, and endocrinology, is the Noaber Foundation Professor of Aging Research at Mayo Clinic. He studies cellular senescence, discovered the first agents that selectively eliminate senescent cells - senolytics -, and demonstrated they delay, prevent, or alleviate multiple disorders and diseases in pre-clinical models. He published the first gerodiagnostic score of senescent cell abundance and the first clinical trials of senolytic drugs. He has over 290 publications (H index: 98). He is the  Principal Investigator of the NIH Translational Geroscience Network and is involved in 82 interventional and observational clinical studies, President of the American Federation for Aging Research, and was the 2020 recipient of the Irving S. Wright Award of Distinction in Aging Research.

Mo Li is an Associate Professor of Bioscience at King Abdullah University of Science and Technology (KAUST). He earned his BS from Peking University and Ph.D. from the University of Georgia, then trained as a postdoc at the Salk Institute. His research focuses on modelling human diseases, development, and regeneration using pluripotent stem cells, cellular reprogramming, and genome editing technologies. His lab develops novel nanopore sequencing methods for identifying mutations in genetic diseases, genome editing, and the aging process. To date, he has over 70 publications in prestigious journals, including Nature, Science, and the New England Journal of Medicine.

Joan Mannick is the Chief Executive Officer and Co-Founder of Tornado Therapeutics which is developing next generation mTOR inhibitors to extend healthy lifespan. Prior to joining Tornado, Joan Mannick was Head of Research and Development at Life Biosciences and Co-Founder and Chief Medical Officer of resTORbio, which was a spinout of a clinical program targeting aging biology that she led as an Executive Director at the New Indications Discovery Unit of the Novartis Institutes of Biomedical Research. Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School.

Lada helped start and is currently a director of Impetus Grants, which identifies and funds promising longevity research within academia. She is also a Thiel fellow researching the field of epigenetics and molecular tools. Before dropping out, she studied physics and computer science at Northwestern University, with research in computational physics.

Professor Penttinen is the CEO for Gulf CDC, based in Riyadh, Kingdom of Saudi Arabia. He is leading the establishment of this regional Center for Disease Prevention and Control in a scientific and managerial role. He is also a part-time professor at the School for Transnational Governance/ EUI in Florence, Italy. Professor Penttinen is a public health leader with a career of more than 20 years in managing and leading disease prevention and control activities in multiple countries, at local, national and international levels both in the public and private sector. Professor Penttinen led the establishment of epidemic intelligence activities and the scientific and programmatic work on the influenza and other respiratory viruses at ECDC.

Andrew J. Scott is a Professor of Economics at London Business School and Co-Founder of The Longevity Forum having previously held positions at Oxford University, London School of Economics and Harvard University. His research is published in leading academic journals and focuses on longevity and ageing. In particular, it examines how individuals and society can adapt to seize a longevity dividend. His book, “The 100 Year Life”, is a global best seller having sold 1 million copies, and his next book, “The Longevity Imperative”, will be launched in 2024.

Dr. Eric Verdin is the President and CEO of the Buck Institute for Research on Aging – a pioneering biomedical research institute dedicated to ageing and age-related disease. A native of Belgium, Dr. Verdin received his Doctorate of Medicine from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health, and the Picower Institute for Medical Research. Dr. Verdin is also currently a professor of medicine at the University of California, San Francisco. In 2016, Dr. Verdin established his laboratory at the Buck Institute to study the relationship between aging and the immune system.

Sergey Young is a longevity investor and visionary with a mission to extend healthy lifespans of at least one billion people and make longevity more affordable and accessible to everyone. Following 20 years of investment expertise managing PE & VC funds, Sergey founded Longevity Vision Fund (LVF) in 2019 to invest in leading biotech companies targeting the underlying causes of aging. LVF has grown its portfolio to 18 companies across gene therapies and editing, AI-enabled drug discovery, and early-stage diagnostics. LVF was honored as a World Changing Idea in Impact Investing by Fast Company in 2021 and 2022, along with leading global impact investing funds.

Dr. Mehmood Khan’s distinguished career has included several senior corporate roles, including Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo, and President of Global R&D at Takeda Pharmaceuticals.

Before moving into the private sector Dr. Khan was a faculty member in endocrinology at the Mayo Clinic and Medical School, where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. He also led programs in diabetes, endocrinology, metabolism, and nutrition in Minneapolis.

Dr. Khan is a member of the Board of Directors of Reckitt Benckiser and of the Saudi Research, Development, and Innovation Authority (RDIA), Executive Chairman of Life Biosciences, a member of the Saudi National Biotechnology Strategy Steering Committee, and Chairman of the Visiting Committee on Advanced Technology of the United States’ National Institute of Standards and Technology (NIST).

Dr. Khan earned his medical degree from the University of Liverpool School of Medicine, England, and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a Fellow of the Royal College of Physicians in London, a Fellow of the American College of Endocrinology, and an Elected Fellow in the Department of Pharmacology at University of Oxford.

HRH Princess Dr. Al Saud’s distinguished career includes roles at the King Abdulaziz City for Science & Technology (KACST), both as Director of the Saudi National Center for Genomics Technology, and as Director of the Saudi National Pre-Marital Screening Program. She also served as a scientist at the King Faisal Specialized Hospital and Research Center, where she carried out a range of research projects focusing on population genetics.

HRH Princess Dr. Al Saud has served as a member of the National Biotech Strategy Advisory Committee at the Strategic Management Office, and as a member of the National Nutrition Committee at the Saudi Food & Drug Authority, as well as being a past and present member of a number of other notable national and international committees. These include serving as a member of the Project Oversight Executive team for the Saudi Genome Project 2.0 at KACST; the S20 Future of Health Taskforce at the G20 Summit; and a committee member for the Princess Noura Award for Women’s Excellence.

HRH Princess Dr. Al Saud holds a PhD in Genomics of Common Diseases from Imperial College London and a Master’s degree in Genetics and Toxicology from McGill University, as well as a Bachelor’s degree in Clinical Nutrition from King Saud University, Riyadh.

Dr. William Greene’s leadership positions have included founder, biotechnology executive, investor, and clinician. As CEO, he built Iconic Therapeutics through discovery, clinical development and venture financing, leading to a successful sale of the company. He later helmed longevity biotech company Fountain Therapeutics and co-founded digital therapeutics startup Pear Therapeutics. 

Dr. Greene spent 12 years at MPM Capital where he was a Managing Director and member of its Investment Committee, responsible for biotechnology and medical technology investments worldwide. He was also founding Chairman and head of the Investment Committee at the Global Health Investment Fund, a groundbreaking impact-oriented venture fund in collaboration with the Gates Foundation, which successfully scaled both investment returns and health impact simultaneously. 

Earlier in his career, Dr. Greene was an Assistant Professor of Medicine at University of California at San Francisco (UCSF) and led clinical trials and strategy for a variety of therapeutic areas at Genentech. 

Dr. Greene earned his BA from Wesleyan University and his MD from UCSF. He was a Robert Wood Johnson Clinical Scholar at Yale and a Howard Hughes Medical Institute Research Scholar at the US National Institutes of Health (NIH).
 

Dr. Sierra’s career has spanned academia, industry and government, including his role as Director of the Division of Aging Biology at the NIA/NIH, from 2006 to 2019, where he was an important contributor to the development of the concept of Geroscience, including the creation and leadership of the trans-NIH Geroscience Interest Group (GSIG). Before joining Hevolution in 2022, he was Director of Geroscience for Inspire.

Dr. Sierra holds a Ph.D. in Biochemistry and Molecular Biology from the University of Florida and was an Assistant Professor at the Medical College of Pennsylvania, and an Associate Professor at the Lankenau Institute for Medical Research in Pennsylvania.

Sophia Pathai, MD, PhD, MSc is a physician with over 20 years of clinical and professional experience, including as an ophthalmologist in the UK’s National Health Service (NHS), as a clinician scientist and faculty member at the London School of Hygiene & Tropical Medicine (LSHTM), and as a Staff Ophthalmologist on the Orbis Flying Eye Hospital. She later transitioned to the corporate sector, serving in global leadership roles in clinical development and medical affairs at Roche, AbbVie, and Johnson & Johnson.

Dr. Pathai holds an MBBS (medical degree) and BSc in Tumor Biology from University College London Medical School, and a Masters in Epidemiology and PhD from LSHTM. Her PhD, which was funded by a Wellcome Trust Clinical Fellowship, investigated clinical aspects of accelerated biological aging. She is a Member of the Royal College of Ophthalmologists (London), a Member of the Faculty of Pharmaceutical Physicians, and a Fellow of the Royal Society of Medicine. She was a mentor for the Johnson & Johnson WiSTEM2D Scholars Award Program and is a board member of Orbis UK.

Salman AlAsiry, Ph.D., Esq previously held various legal, academic, and executive positions at the Saudi Central Bank (formerly known as the Saudi Arabian Monetary Authority); Duke University; the Institute of International Finance; Taibah University; Taibah Valley Company; the Vision Realization Office of the Saudi Ministry of Health; and Health Holding Company. 

Dr. AlAsiry holds Master's and Doctorate degrees, with honors, from Duke University School of Law.  

Viviana Perez, PhD is a scientist with a focus on the biology of aging and geroscience. She was formerly with the US’ National Institutes of Health (NIH) and National Institute on Aging (NIA). At the NIA she served as Program Coordinator and a member of the Leadership Team for the NIH Common Fund on Cellular Senescence (SenNet Consortium) with a $190 Million budget from the Office of the NIH Director. Her responsibilities included coordinating the activities of 19 NIH Institutes, as well as supervision of all activities in SenNet, with full voting rights in all funding decisions. 

Prior to that, Dr. Perez was a tenured associate professor in the Department of Biochemistry and Biophysics at Oregon State University (OSU), as well as Principal Investigator at the Linus Pauling Institute at OSU. During her research career, she was continuously funded from a variety of Federal and non-Federal sources. She has published numerous papers in peer-reviewed scientific journals.

Dr. Perez holds a PhD in Biomedical Sciences, a Pharmaceutical Chemist degree (equivalent to MS) and a bachelor’s degree in chemical and pharmaceutical science, all from the University of Chile in Santiago, Chile. She chairs the Biological Sciences Section of the Gerontological Society of America (GSA). 

Dr. AlShaibani is the Chief Executive Officer of the Health Sector Transformation Program in Saudi Arabia. He spearheads a dedicated team that is accountable for strategizing and supervising the implementation of a holistic program with the goal of revolutionizing and enhancing the healthcare system within the nation. Dr. AlShaibani graduated from King Saud University in Riyadh and completed his training in Renal Transplant and Vascular Surgery in Oxford, England. During his time at King Faisal Specialist Hospital and Research Center, he held various positions, including Executive Director of Medical and Clinical Operations. Prior to his current role, he held key positions in the Ministry of Health, such as the Deputy Minister for Planning and Transformation and Director of Vision Realization Office.

Alexandra is a Co-Founder and Venture Partner at Apollo Health Ventures, a leading venture capital fund focused on biomedical innovations to enhance human health and longevity. As a trained pharmacist and biomedical science PhD, Alexandra followed her passion for improving healthy longevity. During her PhD studies at Harvard Medical School, she focused on investigating the molecular mechanisms that contribute to cellular aging and may be targeted to increase mammalian health span. After her PhD, Alexandra worked with The Boston Consulting Group where she specialized on biopharma strategy to drive the development and commercialization of innovative therapeutics. At Apollo, Alexandra is leading the venture creation programs, conceptualizing innovative biotech ventures that target the aging process at the molecular level.

John Beard, MBBS PhD, is Irene Diamond Professor and Director of the International Longevity Center- USA at Columbia University, New York. He was previously the Director of Ageing and Life Course with WHO in Geneva. He was lead writer for the World Report on Ageing and Health which underpins the current UN Decade of Healthy Ageing, oversaw development of the Integrated Care for Older People (ICOPE) programme, and established the Global Network of Age-friendly Cities and Communities in 2012. He has worked extensively with the World Economic Forum and participated in the US National Academy of Medicine Commission on Healthy Longevity.

Professor Filipe Cabreiro, PhD, is a Professor at the University of Cologne, Germany, and Imperial College London, UK. Professor Cabreiro is a trained biochemist, who has worked on understanding the biological mechanisms underlying molecular stress protection, metabolism and ageing. He held previous roles at Universite Paris Diderot and University College London. His seminal work led to a paradigm shift in the use of C. elegans for studying host-microbe-drug interactions in the context of ageing. He was awarded an EMBO Young Investigator award and a Royal Society/Wellcome Sir Henry Dale Fellowship, for his important contribution to science on the role of the microbiota in the regulation of the effect of pharmacological compounds on host physiology. Over the years, his lab identified signalling and biochemical pathways in bacteria regulating metabolite availability with the capacity to regulate host physiology and ageing. His research aims at developing strategies targeting the microbiota to treat metabolic disease and aging in humans.

Dr. Ana Maria Cuervo MD PhD is professor and co-director of the Institute for Aging Research at Albert Einstein College of Medicine. She is a recognized leader in the field of biology of aging for her studies on the role of protein degradation in aging and age-related disorders, with emphasis in metabolic conditions and neurodegenerative disorders. She has been the recipient of prestigious awards in cell biology and biology of aging and is an elected member of the Valencian Royal Academy of Medicine, the Spanish Royal Academy of Sciences, The Spanish Royal Academy of Pharmacy and the American Academy of Arts and Sciences. In 2019, she was elected to the National Academy of Sciences.

Dr. Hippolyte Fofack has more than 20 years of experience in development economics, international trade, banking, international finance, and academia. He has served in several capacities with the World Bank Group, including as head of the Macroeconomics and Growth Program. Fofack is a fellow of the African Academy of Sciences and a member of the American Economic Association and the African Finance and Economic Association. Fofack has published extensively and served as guest editor of the World Bank Economic Review, Economic History of Developing Regions, and Journal of African Trade.

Henk Heidekamp MSc has a master’s degree in Toxicology and Nutrition from the Open University, the Netherlands. During his career at the University Medical Center Groningen (UMCG), he gained a vast experience in working within laboratory environments. He joined the European Research Institute for the Biology of Ageing (ERIBA) as Managing Director in Spring 2010. The establishment of ERIBA, officially opened in 2013, represents a flagship project of the Healthy Ageing programme at UMCG. At ERIBA, Henk is responsible for a vast and broad range of activities. He also acts as Managing Director of the pre-clinical cluster Biomedical Science and Technology.

Brad Jakeman has a passion for developing category-disruptive business models and marketing programs that challenge the status quo and build famous, world-class brands with a focus on sustainability. Brad is currently the Co-Founder and Managing Partner of Rethink Food, a social-impact venture fund focused on investing in entrepreneurs who are building businesses and technologies that expand access to healthy food, while reducing the harmful impact of the legacy food system on the environment. As Co-Founder and Managing Partner of Rethink Food, Jakeman identifies, invests in, and helps scale businesses that are digitally disrupting the legacy food system to make it more equitable and sustainable. Rethink’s vision is to help create a world where healthy, nutritious food is ubiquitously available and affordable; and where the negative impact on the environment caused by how we make, ship, and sell food is substantially reduced.

Dr. Kritchevsky is the Toby R. Alligood, MD Endowed Professor in Geroscience at the Wake Forest University School of Medicine. He leads the Sticht Center for Healthy Aging and Alzheimer’s Prevention and the Pepper Older Americans Independence Center.  He received his doctorate in epidemiology from the University of North Carolina in 1989.  While at the University of Tennessee Health Science Center (1989-2003) he was a founder of the Health ABC Study. He co-leads the Translational Geroscience Network and the Muscle, Mobility and Aging (SOMMA) Study. He is a former editor of the Journal of Gerontology: Medical Sciences.

Professor Nic Palmarini is the Director of the UK's National Innovation Centre for Ageing (NICA). Before that, he was a Research Manager and Ethics AI Lead at the MIT-IBM Watson AI Lab and Global Manager, AI for Healthy Aging at IBM Research USA. Previously, he was Director of the Human Centric Solutions Centre in Paris and Smarter City SME. He holds more than a decade of experience in applied research on supporting healthy longevity and a deep expertise in bridging academic and industrial research with real-world applications. He is the creator of City of Longevity and the Internet of Caring Things programmes.

Dr. Michael Ringel has been at BCG 25 years and is currently Managing Director and Senior Partner. He is on the Board of Hevolution US, the 501(c)(3) organization focused on extending healthy aging for the benefit of all humanity, the Board of AFAR, one of the oldest organizations supporting healthy aging through biomedical research, and an active advocate for longevity science and innovation. Dr. Ringel holds a B.A. summa cum laude in biology from Princeton, a Ph.D. in biology from Imperial College, and a J.D. cum laude from Harvard Law School. 

David Rundell is widely regarded as one of America’s foremost experts on Saudi Arabia. He served as an American diplomat for thirty years, fifteen of which were spent in Saudi Arabia. He is the author of Vision or Mirage, Saudi Arabia at the Crossroads. He is a regular contributor to Newsweek and his views on the Middle East and oil markets have appeared in Forbes, Bloomberg, and CNN among many others.

Professor Julian Savulescu is the Chen Su Lan Professor in Medical Ethics at the National University of Singapore (NUS), where he directs the Centre for Biomedical Ethics. He is an award-winning ethicist and moral philosopher trained in neuroscience, medicine, and philosophy, going on to hold the Uehiro Chair in Practical Ethics (2002) at the University of Oxford, where he founded the Oxford Uehiro Centre for Practical Ethics in 2003, before moving to NUS in 2022. He is also a Distinguished Visiting Professorial Fellow at Murdoch Children’s Research institute and Melbourne Law School.

Diane Ty is the Senior Director of the Milken Institute Center for the Future of Aging, advancing change at the intersection of healthy longevity and financial security. She is a senior advisor at Georgetown University’s Business for Impact at the McDonough School of Business. Ty has held executive-level positions at AARP, AARP Services, Inc., Save the Children, and American Express Company. Ty earned her undergraduate degree from Duke University and a joint MBA (Wharton School)/MA from the University of Pennsylvania. She is on the board of Capital Caring Health and a gubernatorial appointee to the Maryland State Commission on Aging.

Dr. Tareef AlAama is a Deputy Minister at the Saudi Ministry of Health. He is a geriatrician by training, with more than 20 years experience in the health sector. He is responsible for the curative services provided by the Ministry.

Dr. Abdulrahman AlOlayan is a successful founder and entrepreneur with diversified experience in investment initiatives and business leadership in Saudi Arabia and elsewhere. Dr. Abdulrahman has served as the founding CEO of Taibah Valley, an innovation hub focusing on emerging tech in Medina and the founding CEO of Dammam BioTech Valley, a biotech innovation hub. Most recently, he founded Beta Lab, a deeptech VC attracting ventures from around the world.

Dominic joined the British diplomatic service in 1983 and served in several Middle Eastern posts as well as in the USA and Argentina. He was British Ambassador in Iraq (2006-7), Egypt (2007-2011), Libya (2011-12) and High Commissioner in India (2016-2020). Before beginning his diplomatic career, Dominic worked in the Middle East and London as a teacher, researcher, journalist and political analyst. He is an alumnus of Balliol College (Oxford University) where he read Literae Humaniores.

Dr. Juan Carlos Izpisua Belmonte, previously the Roger Guillemin Chair and Professor at the Salk Institute, has contributed towards understanding the molecular basis underlying embryogenesis and early postnatal life, as well as gained insights into how to program and rejuvenate adult and diseased cells. He is developing technologies to program cells to states similar to those observed in the early, healthy stages of life, with the objective of developing universal health therapeutics to overcome human disease and aging.

Lord Bethell is a former Minister and current member of the House of Lords. As Minister for Innovation in the Department for Health and Social Care, he helped lead the national response to the Covid pandemic. He is one of Britain’s foremost campaigners with a twenty-year track record working across government, media, and industry. He has worked at The Sunday Times, the US Senate, and the EU Commission, run as a Conservative parliamentary candidate, run PR companies (Portland and Westbourne), and helped make the Ministry of Sound a global success story.

Jorge Conde is a General Partner on the Bio + Health team, where he focuses on life sciences and healthcare investments across therapeutics, diagnostics, tools, and software. Prior to joining Andreessen Horowitz, Jorge served as Chief Strategy Officer, Chief Financial Officer, and Chief Product Officer for Syros. Jorge was also co-founder and Chief Executive Officer of Knome, a human genome interpretation company acquired by Tute Genomics in 2015. Before that, Jorge worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley.

Jens has more than 20 years of biopharma venture capital and company creation experience and 10 years of operational experience in drug discovery and development. He is currently an Investment Partner at Hevolution. Previously, Jens was Managing Partner at Apollo Health Ventures where he remains a member of the advisory board. Before Apollo, Jens served as President of GSK’s corporate venture fund SR One. Jens is also co-founder and was Managing Director of GSK’s Action Potential Venture Capital. Previously, Jens was a General Partner at TVM Capital leading early-stage investments. Jens is also a Kauffman Fellow and a member of the EU commission-sponsored Gold Track Expert Council.

Dr. Charles Gersbach is the John W. Strohbehn Distinguished Professor of Biomedical Engineering and Director of the Center for Advanced Genomic Technologies at Duke University. His research interests are in genome and epigenome editing, gene therapy, regenerative medicine, biomolecular and cellular engineering, synthetic biology, and genomics. Dr. Gersbach’s work has been recognized through awards including the National Institutes of Health Director’s New Innovator Award, the National Science Foundation CAREER Award, the Outstanding New Investigator Award from the American Society of Gene and Cell Therapy, and induction into the American Institute for Medical and Biological Engineering and National Academy of Inventors. 

Dr. Gurkar received her undergraduate degree in biology from Florida International University and her Ph.D. from Boston University School of Medicine. She completed postdoctoral work at Massachusetts General Hospital / Harvard Medical School & Broad Institute and then at Scripps Research Institute, Florida. She was awarded a K99/R00 Pathway to Independence grant from the National Institute on Aging. Currently, she is an Assistant Professor in the Aging Institute and the Division of Geriatric Medicine at the University of Pittsburgh. Her lab focuses on defining the metabolic and senescence signatures of human aging. She is funded by the NIH, AFAR/Hevolution, National Academy of Medicine Longevity grant, and RK Mellon Foundation. Outside of the lab, Dr. Gurkar is involved in multiple community outreach programs to engage people in ‘healthy aging’ initiatives.

Folkert Kuipers PhD is a Professor of Pediatrics and Scientific Director of ERIBA at the University Medical Center Groningen (UMCG) since 2022. He studied biology/biochemistry and received his PhD at the University of Groningen. From 2008-to 2016, he served as Dean Faculty of Medical Sciences/UMCG and was involved in the realization of the Healthy Ageing program at UMCG, with population cohort Lifelines and ERIBA as flagship projects. He (co-)authored >370 peer-reviewed publications. He serves on the External Advisory Boards of Robert and Arlene Kogod Center for Aging Research, Mayo Clinic, Rochester, MN, USA, and Multidisciplinary Institute for Ageing, University of Coimbra, Coimbra, Portugal. 

Andrew Levin is a Partner and Managing Director on the Investment Team at RA Capital Management and spearheads a drug discovery effort that has led to the formation of several new companies. Beginning in 2012, and prior to joining as Investment Manager, he was a Vice President at H.I.G. BioVentures. Previously he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School.

Andrea B. Maier is a Fellow of the Royal Australasian College of Physicians (FRACP), graduated in Medicine (MD) from the University of Lübeck (Germany), was registered in The Netherlands as a Specialist in Internal Medicine-Geriatrics and was appointed Full Professor of Gerontology at Vrije Universiteit Amsterdam in 2013. She was the head of Geriatrics at the Vrije Universiteit Medical Center from 2012 to 2016. From 2016 to early 2021, Professor Maier served as Divisional Director of Medicine and Community Care at the Royal Melbourne Hospital, Australia, and as Professor of Medicine and Aged Care at the University of Melbourne, Australia. She continued her career at the National University of Singapore as Director of the Centre for Healthy Longevity. Professor Maier’s research focuses on unravelling the mechanisms of aging and age-related diseases. She is heading international longitudinal cohort studies and geroscience interventions. 

Eric oversees BIOAGE’s clinical and computational efforts to bring new therapeutics to the clinic that target fundamental mechanisms of aging. Eric was previously an assistant professor at the University of Toronto, where his research focused on biomarker discovery and characterization in high-dimensional datasets from human cohorts. He completed an HBSc in artificial intelligence, MD, clinical training in pathology, and a research fellowship in computational biology and molecular epidemiology at the University of Toronto, where he held a Canada Graduate Scholarship from the CIHR, and was subsequently a CIHR research fellow. He has published over 15 papers in the areas of molecular biomarker discovery, pharmacogenomics, aging, and diagnostic medicine.

Scott Parazynski is a decorated physician, astronaut, best-selling author, and tech CEO. A graduate of Stanford University and Medical School, he trained for a career in emergency medicine and trauma. In 1992 he joined NASA's Astronaut Corps and eventually flew 5 Space Shuttle missions and conducted 7 spacewalks. Inducted into the US Astronaut Hall of Fame in 2016, he is the first astronaut to have also summited Mount Everest. A prolific inventor, he is the Founder and CEO of OnwardAir, focused on the development of revolutionary electric aircraft. Additionally, he serves on the Boards of several innovative tech companies.

Marco co-founded and leads as CEO of Rubedo Life Sciences driving its mission to develop treatments for chronic age-related diseases and extend a healthy lifespan by selectively targeting pathological cells involved in the biological aging process. As a scientist, he earned a master’s degree in biotechnology, a PhD in Neuroscience, and post-doctoral training in Aging and Stem Cells Biology in the lab of his mentor Prof. Thomas Rando at Stanford University School of Medicine. He then led a research team at Stanford/VA Hospital Palo Alto focused on translational medical research in the fields of aging and regenerative medicine, co-directing the Center of Tissue Repair, Restoration, and Regeneration. He is backed by over 20 years of research with a track record of scientific publications in top-tier journals. Quarta keeps fostering and championing high standards of compliance, ethics, and patient safety in the development of innovative translational therapeutics, putting patients and society at the center of all actions.

Dr. Rando is the Director of the Broad Stem Cell Research Center at UCLA where he is a professor of Neurology and Molecular, Cell, and Developmental Biology. His lab has been a pioneer in both stem cell biology and the biology of aging, having pioneered the use of heterochronic parabiosis in the study of molecular, cellular, and organismal aging. He has published over 200 peer-reviewed articles and he is an elected member of the National Academy of Medicine and the American Academy of Arts and Sciences. Dr. Rando is also a scientific founder and Chairman of the Board of Fountain Therapeutics, a platform company based on the understanding of cellular aging for drug discovery for the treatment of chronic-age-related diseases.

Sourav is Partner & Head of Strategy at the Longevity Vision Fund, a leading longevity impact fund partnering with growth-stage biotechnology companies developing therapeutics, diagnostics, medical devices, and innovations aimed to extend the healthy human lifespan. Previously, Sourav was a founding executive of Celularity (NASDAQ: CELU)—the first spinout of Celgene, and is a scientific co-founder of Codeable Therapeutics. Sourav is a 2023 Millennium Fellow of the Atlantic Council and was named to the Forbes 30 Under 30 list for Healthcare. Sourav holds an A.B. in Molecular Biology and Biochemistry from Dartmouth College.

Dr. Andrew Adams serves as Sr. Vice President of Neurodegeneration Research and is Co-Director of the Lilly Institute for Genetic Medicine. Dr. Adams is responsible for leading the discovery of new types of therapies, such as genetic medicines at Lilly, via both internal research and robust collaborations with external partners. These novel approaches will allow access to previously undruggable targets across the breadth of therapeutic areas at Lilly, as well as potentially open novel avenues of clinical investigation. Dr. Adams holds a degree in biology and a doctorate in zoology from the University of Aberdeen, Scotland. Prior to joining Lilly in 2011, Andrew was a postdoctoral fellow at Harvard Medical School studying the neurobiology of anorexia nervosa. During his time at Lilly, he has served in roles in early discovery, and external innovation and as a leader of Lilly’s early trailblazer teams, championing new ways to bring Lilly science to patients with speed.

Jim Scopa is a director and investor in entrepreneurial life sciences companies, most recently serving as a director of DICE Therapeutics (sold to Eli Lilly August 2023 for $2.4 billion) and of Adverum Biotechnologies and Neuron23, Inc. Previously, Jim was a co-founding director of Semma Therapeutics (sold to Vertex Pharmaceuticals for $950 million September 2019) and of True North Therapeutics (sold to BioVerativ for $800 million July 2017). He served as a Managing Director and member of the Investment Committee of MPM Capital, a global venture capital firm (2005-2017). Jim was a fellow at Stanford Distinguished Career Institute in 2017-2018 with a focus on translation of research to clinical development.

Dr. AlMubarak is a senior clinical scientist at King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. She received her B.Sc. in biochemistry from King Saud University. AlMubarak earned her Ph.D. in neuroscience from the University of Edinburgh, U.K. Her postdoctoral studies were spent at the University of Oxford under the department of physiology anatomy and genetics. Dr. AlMubarak has more than 16 years of experience in areas such as neuroscience cell biology and genetics of complex disorders. Her research interest lies on unravelling the molecular and cellular basis of neurodegenerative and neurodevelopmental disorders. Dr. AlMubarak and her team lead pioneering studies on the genetics of Parkinson’s disease and Autism in Saudi Arabia. She is an advocate of a team science approach evident by her wide network of national and international collaborations.

Anas AlMudaifer is the Chief Executive Officer of the Human Capability Development Program (HCDP), one of the Saudi Vision 2030 Programs. Anas has extensive experience in public transformation, e-transformation, and strategy and management consulting in local and international organizations. Prior to joining HCDP, he was the Strategy and Planning Vice President at the National Transformation Program (NTP). Previously, Anas led the establishment of Elm Company Corporate Venture Capital as the Emerging Business Executive Manager and previously managed the building of the Strategy and Transformation Consulting practice as the Consulting Executive Manager. He also led major transformation programs in various public sector entities. Anas has diverse areas of expertise, including strategy formulation and execution, organizational design and change, business process reengineering, policy design, human resources development, and business and technology alignment.

Dr. Ann Beliën, CEO & Founder matured Rejuvenate Biomed in 5 years from a discovery start-up to a clinical-stage company. She has over 22 years of experience in drug development from bench to market, which she acquired throughout multiple international assignments. Ann developed from scientist to operational and strategic roles across multiple diseases including external and open innovation (therapeutics and prevention). Ann served as due diligence representative for R&D at J&J and served on the management board of Janssen Prevention Center for 5 years. She joined J&J in 2000, after a postdoc at ETH, Zürich, Switzerland. She holds a PhD from the University of Irchel, Switzerland and a master’s degree from the VUB, Belgium.

Marc P. Bernegger is a serial-tech entrepreneur who has been following developments in the field of longevity since 2009. Besides co-founding the longevity company-builder Maximon and the Longevity Investors Conference, he is involved in the crypto hedge fund AltAlpha Digital and is among others in the board of CfC St. Moritz and the Swiss Blockchain Federation. Marc explored Bitcoin in 2012 and was a founding shareholder and board member of Crypto Finance Group (acquired by Deutsche Boerse in 2021). Marc started his entrepreneurial journey by founding the party platform usgang.ch right after college (acquired by Axel Springer Media). He is also a co-founder of amiando, a ticketing platform, which was purchased by Xing and named “Global Technology Pioneer” by the World Economic Forum (WEF). Marc holds a master’s degree in law from the University of Zurich and is an alumni of the Singularity University.

David Berry is Founder and CEO of Valo Health.  He has served as a General Partner at Flagship Pioneering, having founded over 25 companies. David played an instrumental role in the conception and implementation of Flagship Labs, Flagship’s company creation unit, which is now the foundation of all its companies. David has been broadly recognized as a world-leading innovator: elected as a Young Global Leader by the World Economic Forum, named as Innovator of the Year by Technology Review from amongst its Annual TR35 list, and selected as one of 12 Innovators Reshaping Reality by the U.S. State Department, alongside pioneers such as Tim Berners-Lee.  He holds over 200 patents and patent applications. David and his companies have been awarded with over 150 additional awards and honors. David currently serves on the United Nations Sustainable Development Solutions Network (UN SDSN), where he was a Founding Leadership Council Member.  David received his MD from Harvard Medical School and his PhD from MIT in Biological Engineering

Dr. Lon R. Cardon is the President and CEO of The Jackson Laboratory. Previously, he was Chief Scientific Officer and Chief Scientific Strategy Officer at BioMarin Pharmaceutical Inc. (2017-2021) and Senior Vice President at GlaxoSmithKline plc (2008-2017). He held positions at the University of Oxford, including head of bioinformatics and statistical genetics at the Wellcome Trust Centre and later as a professor. He is an elected fellow of the UK’s Academy of Medical Sciences and the American Association for the Advancement of Science. Cardon conducted his Ph.D. research at the University of Colorado Boulder and postdoctoral training at Stanford University.

Dr. David Furman is the Director of the Stanford 1000 Immunomes Project, and Associate Professor and Director of the Bioinformatics Core at the Buck Institute for Research on Aging. Dr. Furman obtained his doctoral degree in immunology from the School of Medicine, University of Buenos Aires, Argentina, for his work on cancer immune-surveillance. During his postdoctoral training at the Stanford School of Medicine, Dr. Furman focused on the application of advanced analytics for studying aging in the human immune system. During a sabbatical year at University of Bordeaux, France, Dr. Furman studied the involvement of the endocrine and immune systems in human aging and in kidney transplantation, and then he helped create the Systems Biology Department at the Sidra Medical Research Center in Doha, Qatar. Before joining as a Principal Investigator at the National Scientific and Research Council, Buenos Aires, Argentina, Dr. Furman returned to Stanford as Senior Scientist at the Institute for Immunity, Transplantation and Infection (ITI), where his work involved the use of Machine Learning tools to better define the role of the immune system in cardiovascular aging.

Dr. Khizer Khaderi is a Clinical Associate Professor at Stanford University's Byers Eye Institute and the founder of both the Stanford Human Perception Laboratory and Vision Performance Center. A globally recognized Neuro-Ophthalmic surgeon and futurist, his expertise spans AI, VR, AR, MxR, wearables, applied neuroscience, and human-machine interactions. Khaderi crafts human intelligent systems by merging biological and computational principles. His multifaceted experience covers consumer electronics, gaming, healthcare, and more, with numerous invention patents to his credit. Recognized in “40 under 40”, he advised President Obama’s Science Council and consults for giants like Google, Microsoft, Apple, and the World Health Organization.

Ronjon Nag is an Inventor, Adjunct Professor at Stanford University, founder of Agemica (longevity science) and R42 Group (venture capital). He has won the 2021 IEEE-SCV Outstanding Engineer award, the Institute of Engineering and Technology Mountbatten Medal, the $1m Verizon Powerful Answers Award, the 2023 COGX (90,000 attendee AI conference) Lifetime Achievement Award and the 2023 MIT Great Dome Award. He is a part owner of 100 AI/Biotech start-ups. His companies have been sold to Apple, BlackBerry, and Motorola. He teaches courses on AI, Genes, Ethics, Longevity Science and Venture Capital. His degrees are PhD (Cambridge), MS (MIT), BSc (Birmingham).

Daniel Oliver is a co-founder and the CEO of Rejuvenate Bio, a startup out of George Church’s Lab at Harvard Medical School working on targeting the driver of age-related disease through the use of novel gene therapies. Rejuvenate Bio has demonstrated the ability to treat multiple chronic conditions with a single gene therapy and is the first group to show a doubling of remaining lifespan in mice utilizing epigenetic reprogramming. Prior to Rejuvenate Bio, Daniel was awarded a Blavatnik Fellowship during which he co-founded Voxel8. Voxel8 was named one of the top 9 innovations at CES and one of the top 50 most innovative companies by the MIT Technology Review. Daniel received his M.B.A. from Harvard Business School and has degrees in Mechanical Engineering and Business from the California Institute of Technology.

Kush Parmar, MD. PhD. is a Managing Partner at 5AM Ventures. He serves as a Director on the Boards of Ensoma, Entrada, GlycoEra, Precede, and Rallybio. He was previously a Board Member for Akouos (acquired by Eli Lilly), Arvinas, Audentes (acquired by Astellas), Vor Biopharma, and Novira (acquired by J&J). Dr. Parmar serves on the Advisory Boards of Harvard Medical School, Penn Medicine, Princeton University’s Department of Molecular Biology and is a Fellow of the Society of Kauffman Fellows. He holds a Ph.D. in Experimental Pathology and an M.D. from Harvard Medical School. 

Brock Reeve is the CEO of EOS BioInnovation, an investment company launched in 2022 to accelerate the formation of companies in the regenerative medicine field. EOS is dedicated to incubating and seeding companies across modalities and indications based on research from leading academic labs. Prior to forming EOS, Brock was the Executive Director of the Harvard Stem Cell Institute. Brock came to HSCI from the commercial sector with extensive experience in both management consulting and operations for life science and medical device companies. Brock was the initial CEO of IVIVA Medical (recently acquired) and is on the Board of Thrive Bioscience and a Board observer at Axonis Therapeutics. 

Seema Verma is SVP & GM, Oracle Life Sciences. She is a national health care expert and most recently served as a Senior Advisor to private equity firms TPG and Cressey & Co, serving on the Cressey Distinguished Executive Committee. She also served on the Board of Directors for Lumeris, Monogram, Wellsky, ClaimsXten, Lifestance and ShiftKey. Additionally, she provided advisory services to a variety of early stage and large public health care companies including national payers and technology companies focusing on strategy, value creation and operations. 

Dr. Hanadie Yousef, an expert on the biology of aging and mechanisms underlying tissue degeneration, is co-founder and CEO of Juvena Therapeutics, a biotechnology company mapping the therapeutic potential of secreted proteins to develop biologics that prevent and reverse chronic and age-related diseases. Juvena’s proprietary platform has enabled the identification, preclinical validation, and lead optimization of three novel drug candidates, including one expected to enter the clinic in 2024, and multiple discovery candidates. Dr. Yousef was named to Insider’s “30 under 40 in Healthcare,” Endpoints’ 20 under 40” and Pharmaceutical Executives’ “Emerging Leaders” in 2023 and earned the Biocom California Life Science Catalyst Award in 2022.

Dr. Alromaih is a King Faisal Specialist Hospital and Research Centre Alumni, where he served as a scientist and developed multiple basic and translational research projects to study renal function and failure. Prior to that, he completed his Ph.D. training at the Faculty of Medicine, Department of Laboratory Medicine and Pathology, University of Toronto, then pursued a 5-year postdoctoral fellowship at Harvard Medical School. Dr. Alromaih joined Hevolution in the summer of 2021 where he currently works to support the efforts to advance healthspan research worldwide. 

Brian Kennedy, Ph.D. is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at the National University Singapore (NUS). He serves as Director of (1) the Centre for Healthy Longevity at the National University Health System in Singapore, (2) the NUS Medicine Healthy Longevity Translational Research Programme, and (3) the Asia Centre for Reproductive Longevity and Equality at the NUS School of Medicine. Prof. Kennedy was formerly President and CEO of the Buck Institute for Research on Aging and served as a professor there through 2020. He has an adjunct appointment at the Department of Biochemistry at the University of Washington, where he was a faculty member from 2001 to 2010. Additionally, Prof. Kennedy is a Co-Editor-In-Chief of Aging Cell, a peer-reviewed, open-access scientific journal. Prof. Kennedy also served as Visiting Professor at the Aging Research Institute at Guangdong Medical College in China from 2009 to 2014. Prof. Kennedy’s Ph.D. was performed in the laboratory of Leonard Guarente at the Massachusetts Institute of Technology, where he published the first paper linking Sirtuins to aging.

Tahir Malik is a transformative global industry leader with over 28 years of international experience across Europe, Asia, the Middle East, and Latin America. Tahir is currently the Executive Vice President of Africa Middle East for Reckitt, leading its operations in +70 countries and seven regional business units. Prior to this, Tahir led Latin America and ASEAN as Regional Head for Reckitt, and Turkey and West Asia as Country CEO. Tahir also has over 15 years of international experience with Procter & Gamble working in leadership positions in Switzerland, Belgium, Pakistan, and the Arabian Peninsula – working across HQ and countries and leading business in Europe, the Middle East, and Africa.  

Dr. Hanan Balkhy was appointed Assistant Director-General for Antimicrobial Resistance (AMR) in 2019, and she was elected as the new Regional Director-Elect for the Mediterranean Region in October 2023. In ADG’s role, she provides political and technical leadership to curb the devastating health and economic burdens of drug resistance. The work includes a focus on supporting countries to implement AMR National Action Plans and strengthening the global response, including through multi-sectoral collaboration with the Food and Agriculture Organization, World Organization for Animal Health, and United Nations Environment Programme. Prior to joining WHO, Dr Balkhy was Executive Director for Infection Prevention and Control at Saudi Arabia’s Ministry of National Guard and the first Chairperson of the Infectious Diseases Research Department at the King Abdullah International Medical Research Centre in Riyadh. She also served as Director of the WHO Collaborating Centre for Infection Prevention and Control and Antimicrobial Resistance at King Abdulaziz Medical City Hospital. 

Dr. Yury Kukushkin joined the Hevolution as Investment Partner in 2023 from JDRF T1D Fund, in which he was a Managing Director. While there, he focused on autoimmune, metabolic, and regenerative medicine companies to cure type 1 diabetes. Prior to that, Yury was a Principal at 4BIO Capital, a London-based fund investing in public and private life sciences companies. At 4BIO, he focused on gene and cell therapies, PROTACs, RNA medicines, and targeted therapies and delivered top-quartile returns for the fund. Prior to this role, Yury was an Associate at RBV Capital, an early-stage life sciences venture fund. Earlier in his career, Yury worked in various roles in a boutique biotech consulting company. Yury received his M.S. in Biochemistry with specialization in Virology from Moscow State University and a Ph.D. in Biochemistry from Max Planck Institute of Biochemistry, Martinsried and LMU, Munich, Germany.

Jim is a British entrepreneur who is a recognized thought leader in the field of aging research and longevity.  His groundwork in the field is summarised in the book “Juvenescence”. Jim and his partners have set up Juvenescence, a company developing therapies for aging and the diseases of aging. Jim sits on the Board of Trustees of the Buck Institute for Research on Aging, and the American Federation for Aging Research. He is also a trustee of the Lifeboat Foundation, is an Honorary Fellow of Oriel College at the University of Oxford, and sits on the Advisory Board of the Milken Institute’s Centre for the Future of Aging. Jim has been honoured by the AFAR with the George E. and Marie J. Doty Award for his support of aging research.

Laura Niedernhofer joined the University of Minnesota in July 2018 to direct the new Institute on the Biology of Aging & Metabolism (iBAM) and the Medical Discovery Team on the Biology of Aging. She is also a Professor in the Department of Biochemistry, Molecular Biology and Biophysics at UMN. Dr. Niedernhofer’s expertise is in DNA damage and repair, genome instability disorders, cellular senescence, and aging. Her research program is centered on studying fundamental mechanisms of aging and developing therapeutics to target them. Her research program implements a murine model of a human progeroid syndrome caused by a defect in DNA repair. She contributed to the discovery of a new class of drugs called senolytics. Laura has served on the study section for NCI, NIEHS and NIA. She has been awarded for research in aging, cancer, and environmental health science. 

Prof. Orlando got his degree in Molecular Biology at the University La Sapienza in Rome, Italy. After pioneering the early days of molecular Epigenetics at the University of Heidelberg, he established his own lab at San Raffaele Hospital in Milan and then Telethon Foundation at Santa Lucia Hospital in Rome, spearheading the first Italy Flagship program on Epigenetics (30M USD). In 2013 he was recruited at KAUST where he established the Environmental Epigenetics Research program. He is an elected member of the European Molecular Biology Organization (EMBO), an Associate member of the Longevity Medicine Society, served as President of the Italian Society for Molecular Biology and in 2007 received a Knighthood from the Italian Republic President.

Dr. AlDriwesh is a clinical scientist and an assistant professor of molecular biology and microbiology at King Saud bin Abdulaziz University for Health Sciences. She graduated from King Saud University in 2009 and completed her postgraduate studies in the United Kingdom in 2017.
Dr. AlDriwesh and her team received grants from King Abdullah International Medical Research Centre to study the gut microbiome in healthy and diseased states in Saudi Arabia with the passion for benefiting the health and well-being of Saudi citizens and for contributing to the global efforts being made to understand the power of the human microbiome.

Dr. Anas Abdel Rahman, a clinical scientist at KFSHRC's Center for Genome Medicine, leads the metabolomics facility in Clinical Genomics. As an Associate Professor at Alfaisal University, he has published 100+ peer-reviewed manuscripts in bioanalytical chemistry. Dr. Abdel Rahman's expertise in metabolomics, lipidomics, and proteomics has significantly contributed to global scientific knowledge. A dedicated mentor, he has trained over 70 students.

Dr. Tlili Barhoumi is a Research Scientist at KAIMRC. Previously, he was a Research Associate scientist at McGill University for 2 years, and a Postdoctoral fellow for 5 years at McGill University, Canada. He received his PhD from McGill University and Avignon University in Canada/France. MSc1 and MSc 2 from UFC University France. Dr. Barhoumi’s research interests are mainly the implications of innate and adaptive immune systems in vascular biology and hypertension, as well as cardiometabolic diseases associated with inflammation and vascular damages (CVD, diabetes, obesity, kidney dysfunction). He also has a background in exercise physiology associated to cardiovascular diseases.

Jamie Heywood is an MIT-trained mechanical engineer who entered biomedicine after his brother was diagnosed with ALS in 1999. Prior to founding Alden Scientific, a digital biology company that develops advanced individual predictions to manage health, disease, and aging, Jamie founded the ALS Therapy Development Institute, PatientsLikeMe, and AOBiome, and co-founded Genetic Networks, The SocialMedwork, and iCarbonX International. His focus has been on addressing fundamental improvements in the discovery and development of treatments and management of health and disease and in empowering individuals. Jamie’s work has been profiled in The New Yorker, 60 Minutes, TEDMED, Pulitzer Prize winner Jonathan Wiener’s book, His Brother’s Keeper, and the Sundance award-winning documentary So Much So Fast.

Dr. Mansour Turki AlHajlah is a Lawyer, Managing Partner at MTH&Partners Law Firm, and an Advisor for Hevolution Foundation. Previously, Dr. AlHajlah was the Vice-President of the Health Sector Transformation Program (HSTP) for Legislation and Legal Affairs. In his roles, he has led the legal efforts of Corporatizing MoH facilities and has also led the legal efforts of proposing the bill of Health Act and proposing the health impact assessment to be a requirement in all supporting documents of any proposed laws or regulations. 

George Vradenburg is the Chairman of the Board of the Davos Alzheimer’s Collaborative, a global public-private-patient Swiss-based foundation engaged in linking and scaling Brain Health research and primary care delivery systems in high-, middle- and low-income countries. DAC was launched in Davos in 2021 by the Global CEO Initiative on Alzheimer’s Disease and the World Economic Forum. Mr. Vradenburg is also the Chairman and Co-Founder of UsAgainstAlzheimer’s, a US-based venture philanthropy and advocacy organization committed to increasing the scale and speed of therapeutic and public health initiatives to prevent Alzheimer’s and Related Dementias. Mr. Vradenburg served as a senior executive at CBS, Fox, and AOL/Time Warner and is a resident of Washington DC, a member of the Council of Foreign Relations and the Economic Club of Washington, and the former Chair of The Phillips Collection art museum. 

Dr. Westphal is Co-founder and General Partner of Longwood Fund and has spent over 20 years as a biotech CEO, entrepreneur, and investor. Dr. Westphal has been the co-founder, CEO, and lead investor of seven biotechnology companies that have completed initial public offerings (IPOs) created sustained market value of over $45 billion, and have developed and received FDA approval for over 10 important drugs. Dr. Westphal was also co-founder of Alnara Pharmaceuticals (acquired by Eli Lilly in 2010); co-founder/CEO of DEM Bio Pharma; co-founder/CEO of Immunitas Therapeutics; co-founder/Chair of Solu Therapeutics; co-founder of Tome Biosciences; co-founder of Pyxis Oncology (NASDAQ: PYXS); and co-founder of Concert Pharmaceuticals (NASDAQ: CNCE, acquired by Sun Pharma in 2023). Companies founded by Dr. Westphal have created thousands of jobs in the Boston area.

Since October 2016, Professor AJjadhey has been appointed as the Executive President of the Saudi Food & Drug Authority (SFDA), based in Riyadh. He is leading his energetic team to achieve the SFDA vision to be a leading international science-based regulator to protect and promote public health. He worked with stakeholders to develop and execute the SFDA strategy. In his role in SFDA, he is responsible for observing the safety and effectiveness of food and drugs for humans and animals, cosmetics, pesticides, and the safety of medical devices and their impact on public health in the Kingdom of Saudi Arabia. In addition to his leadership responsibilities at SFDA, he is a member of several boards including the Saudi Health Council, Saudi Standards, Metrology and Quality Organization, Saudi Center for Disease Prevention and Control, National Unified Procurement Company, Saudi Patient Safety Center and National Institute of Health Research.

Matt Kane is the Chief Executive Officer and Director of Tune Therapeutics.
 A veteran biotech leader with deep experience in advanced genetic medicines, Matt was previously the co-founder and CEO of Precision BioSciences – a company focused on developing gene and cell therapies using a novel gene editing platform.
 As CEO, he led a team that raised over $400M in equity and debt financing, including an IPO in 2019, formed partnerships with leading biopharmaceutical companies valued at over $4.7B, and advanced four unique genetic medicines into human clinical trials. Matt has nearly twenty years of experience in the life sciences industry and was formerly with Suros Surgical Systems, later acquired by Hologic. 
He received his B.S. and M.S. from the Rose-Hulman Institute of Technology, and an MBA from Duke University.

Matt von Zirkelbach serves as Associate Vice President responsible for Strategy and Operations, as well as the Chief of Staff for Lilly Genetic Medicines (LGM). Matt’s focus is driving the long-term strategy, organizing and prioritizing scientific efforts, collaborating with external partners, and designing systems to enable LGM to succeed in its mission. Matt holds a Bachelor of Science in Biological Science and a Master of Science in Engineering from Purdue University and Rose-Hulman Institute of Technology, respectively. Prior to joining Lilly, Matt has served in a multitude of capacities in his 15 years in the industry. These roles ranged from global capacities such as Quality oversight for the entire lifecycle of products to plant management and operations. 

Dr. Francisco Leon is the Chief Scientific Officer and Co-Founder of Provention Bio, a Sanofi Company (acquired by Sanofi in 2023). He is a basic and clinical immunologist specializing in autoimmunity and translational medicine, with academic (including US NIH) and pharma careers. Previously, Dr. Leon was the Co-Founder, CEO and Chief Medical Officer of Celimmune, acquired by Amgen in 2017. He also held senior positions at Bristol Myers-Squibb, MedImmune/AstraZeneca, and Centocor/Janssen/J&J. Dr. Leon led or participated in the early development of 6 drugs which reached the market, most recently teplizumab (Tzield®) for delay of onset of clinical Type 1 Diabetes and has also co-authored 100+ peer-reviewed articles and book chapters, and 20+ patents.

Anya Sitaram is a documentary producer, conference host and communications consultant specialising in health, environment and international development. A former BBC World news anchor, Anya is a founding director of Rockhopper Media an award-winning television and film production company. Anya has overseen scores of television documentaries which have run on channels around the world including BBC World News, PBS, Discovery, Nat Geo and Al Jazeera among others. Anya has been moderating high level conferences for the European Commission, UN bodies, international NGO’s and leading corporations for the last 15 years on topics including global health and environment, climate, food security, agriculture, science and technology. Anya began her career as a BBC trainee before becoming ITN Health and Science Correspondent and later a presenter on the BBC’s flagship science programme Tomorrow’s World.

Rawan Radwan is an accomplished journalist with over a decade of experience in the GCC media landscape. She is currently the Deputy Section Editor for the Spotlight and Special Projects section at Arab News, where she covers a wide range of topics, including sustainability, global warming, climate change, culture, reforms, conflict and migration issues, social issues, travel, art, and history. Rawan has interviewed leaders in several of the Kingdom's sectors, as well as influential individuals from around the world.

Ben is a journalist and presenter for BBC News, based in London.  He presents Breakfast, the BBC’s flagship morning news program, and anchors the BBC's domestic and global news channels, BBC News and BBC World News. As a specialist in international business and finance, Ben has travelled extensively and reported for the BBC from around the world.  Before returning to the studio, Ben was based in New York and Washington as the BBC's North America Business Correspondent. Prior to that, Ben spent three years as the BBC's Middle East Business Correspondent.  He reported from Iraq, Syria, Saudi Arabia, Algeria, Lebanon, Tunisia, Egypt, Oman, Kuwait, Bahrain, Qatar, and the UAE, covering breaking news and developing stories. In a career spanning 16 years at the BBC, Ben has reported on wars, hurricanes, riots, and red carpets. He’s also clocked up a fair few air miles. Ben studied International Business and French at the University of Wales in Cardiff followed by a Postgraduate Diploma in Broadcast Journalism.  In 2003, he was awarded a BBC Scholarship.

Sameera AlTuwaijri is the Global Lead on Population and Development at the Health Nutrition and Population Global Practice of the World Bank. She is a clinician with over 10 years of experience in clinical practice before she embarked on studying Public Health. She has a master’s in public health from Harvard University, a Ph.D. in health policy, and a post-doctoral fellowship from Johns Hopkins. For over a decade now, she has been working on reproductive health, demographics, and aging. Prior to joining the World Bank in 2010, she was the regional adviser, RH policy for UNFPA, Arab States, and the director of the ILO's program on Public Health and Safety. From 2012-2015, she was on an external service assignment where she served as the first regional director, of Arab States, UN Women.

Professor Imed Gallouzi has been a Professor of Bioscience as well as COO and Associate Director of KAUST Smart-Health Initiative since January 2021. Previously, he was a Professor of Molecular and Cellular Biology at McGill University for 20 years. After receiving his Ph.D. in Molecular Biology from University Montpellier II, Professor Gallouzi completed postdoctoral training at Yale University. As a world-class scholar in mRNA biology, Professor Gallouzi’s work on the role of in RNA binding proteins and their impact on cellular adaptation to stressful and pathological conditions has led to key contributions in muscle physiology and disease, cancer, and aging.
 

Jordi Naval is currently spearheading the Biotech Sector in Neom, fostering a thriving innovation ecosystem in line with our visionary goals. With over 20 years of transformative leadership in the industry, he has co-founded and led the growth of 6 successful biotech ventures and raised funds over $200 million, with 3 multimillion exits. Jordi has also been instrumental in elevating Barcelona into a global biotechnology hub, drawing in over $1 billion in international investments.

Dr. Khaled AlKharef is Assistant Professor of Health Law and Ethics, Saudi Electronic University. Previously, Dr. AlKharef was a judge at the Ministry of Justice. Dr. AlKharef received his Bachelor’s Degree in Law from Islamic University Of Imam Mohammed Bin Saud, his Master’s Degree in Law from the Higher Institute Of Justice Islamic University Of Imam Mohammed Bin Saud and California School of Law, and is a Doctor Of Juridical Science (Sjd), Suffolk University – Health Law.

Norah AlYusuf, a passionate advocate for holistic well-being, currently serves as the Global Engagement Senior Advisor to the CEO of Vision 2030 Quality of Life Program. In this role, she is dedicated to fostering emerging practices in support of Quality of Life. With a background steeped in leadership roles within the private and non-profit sectors she has consistently driven transformative agendas across communication, strategy, and business operations. Her commitment to well-being extends beyond her professional endeavors.  As a current and founding Board Member of the Saudi Polo Federation, Norah actively promotes a balanced and healthy lifestyle. combining her love for culture, sports, nature & wellness. Hailing from the Kingdom of Saudi Arabia, graduated from UC Santa Barbara, with a BA in Business Economics and Art History, and is a certified Integrative Nutrition Health Coach from the Institute of Integrative Nutrition in New York City.

Professor Peter Bauer, M.D., serves as CENTOGENE's Chief Medical and Genomic Officer, where he combines an extensive clinical and medical understanding of genetic testing with an excellent knowledge of the latest scientific developments. Peter is passionate about turning medical questions into complete and fast analytical processes – ensuring that medically-driven results are brought to clinicians and patients immediately. He received his board certification in Human Genetics in 2006 and previously headed the Molecular Diagnostic Laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Peter has authored more than 250 publications in Neurogenetics, Oncogenetics, Cardiogenetics, and Sequencing Technology.

Fraser Hall is President, Head of Intercontinental Region, which includes Latin America, Australia, Asia, Japan, the Middle East and Africa, as well as Turkey and Russia/CIS. Prior to joining Biogen in July 2020 as Vice President for Latin America, Mr. Hall was with AstraZeneca for 5 years. There, he initially served as Vice President in the global organization, where he led the strategy and launch preparation for a new stroke treatment, and then as Country President for Brazil, where he led the COVID trial program and negotiations on vaccine supply with the Brazilian government. Before AstraZeneca, Mr. Hall worked for Novartis for 13 years. This experience covered leadership and general management roles at country, region and global levels, with extensive work in Asia and developing markets. Mr. Hall holds a Bachelor of Science degree from Aston University and has completed finance and organizational leadership courses at Harvard University and MIT. 

Matt Kane is the CEO of Tune Therapeutics. He was previously the co-founder and CEO of Precision BioSciences, where he led a team that raised over $400M in equity and debt financing, including an IPO in 2019, formed partnerships with leading biopharmaceutical companies valued at over $4.7B, and advanced four unique genetic medicines into human clinical trials. Matt has nearly twenty years of experience in the life sciences industry and was formerly with Suros Surgical Systems, later acquired by Hologic. He received his B.S. and M.S. from the Rose-Hulman Institute of Technology, and an MBA from Duke University.

Dr. Francisco Leon is the Chief Scientific Officer and Co-Founder of Provention Bio, a Sanofi Company (acquired by Sanofi in 2023). He is a basic and clinical immunologist specialized in autoimmunity and translational medicine, with academic (including US NIH) and pharma careers. Previously, Dr. Leon was the Co-Founder, CEO and Chief Medical Officer of Celimmune, acquired by Amgen in 2017. He also held senior positions at Bristol Myers-Squibb, MedImmune/AstraZeneca, and Centocor/Janssen/J&J. Dr. Leon led or participated in early development of 6 drugs which reached the market, most recently teplizumab (Tzield®) for delay of onset of clinical Type 1 Diabetes and has also co-authored 100+ peer-reviewed articles and book chapters, and 20+ patents.

Dr. Peng Leong leads efforts at BioAge to execute strategic transactions that convert prioritized drug targets into a portfolio of therapies for treating diseases of aging, and activities specific to brain aging. Peng has played a key role in building BioAge’s pipeline, including Azelaprag now starting Phase 2 for obesity and muscle atrophy. In prior roles at Merck KGaA, Chiron, Kazia, DRI and investment banking, Peng acquired or sold billions of dollars in pharmaceutical product rights. Dr. Leong received his BSc and PhD in Biochemistry from the University of Toronto, Canada and an MBA from the University of California, Berkeley.

The Honorable Steven Papermaster is the founder, Chairman and CEO of Nano, the molecular data and nanoscale digital technology leader. He has 30 years of experience as a career technology entrepreneur, public policy expert, global speaker, and noted author. Steven’s leadership has included being the founder, chairman, CEO and/or board member for several publicly traded (and successful IPOs) and private companies. Steven was a senior advisor to President George W. Bush and a core architect of domestic and global strategy for innovation, technology, and science. He was a member and co-chair of PCAST – the President's Council of Advisors for Science and Technology, the Human Genome Project, the National Nanotechnology Initiative, Stem Cell/Regenerative Medicine program, and Secretary of Energy Advisory Board. Steven also served as a judge for the White House Fellows, one of America’s most prestigious programs for leadership and public service.